Philip Morris International cigarettes can cause lung disease. Now the company wants to sell medicine to treat it.

Date:

World’s largest cigarette maker is making acquisitions as it pursues a ‘smoke-free’ future. Many scientists are doubtful.

Ruth Tal-Singer spent more than two decades at GlaxoSmithKline, where she was a top scientist studying COPD — a chronic lung disease often related to smoking. She’s published dozens of influential scientific papers. And she now helps run the nonprofit COPD Foundation.

So she was stunned when a recruiter contacted her this summer to see if she would be interested in working with Philip Morris International, the world’s largest listed tobacco company.

“Mind-boggling,” she said.

The tobacco company’s bid to hire Tal-Singer is a piece of a much larger plan by the New York-based company to pivot away from cigarettes and develop new lines of business that go beyond just smoke-free products. Philip Morris International calls it a “Beyond Nicotine” strategy and says it wants to earn $1 billion from these new ventures by 2025.

All cigarette companies know the industry that established their fortunes is fading, as smoking rates decline worldwide. Most are invested in vaping and e-cigarettes. But no Big Tobacco firm has been as aggressive as Philip Morris International in seeking out entirely new ways of making money.

Read full article here.

Todd C. Frankel – Washington Post – 2021-09-02.

Want More Investigative Content?

Curate RegWatch
Curate RegWatchhttps://regulatorwatch.com
In addition to our original coverage, RegWatch curates top stories on issues and impacts arising from the regulation of economic, social and environmental activity in Canada and the U.S.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

MORE VAPING

Vaping Coverage Get it NOW!

Sign Up for Incisive Content!

RegWatch original video is designed to move opinion. Get our videos first and be the first to share.

Your Information will never be shared with any third party